Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8117710 | 1.00 | PARP1 (0.52) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL1283375 | 1.00 | PARP1 (0.52) | PARP1CA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL38666438 | 0.99 | PARP1 (0.51) | PARP1CA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL19947902 | 0.99 | PARP1 (0.51) | PARP1CA1CA2CA4CA9 | |
| Hydrochloric Acid SCHEMBL28497645 | 0.99 | PARP1 (0.51) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL16846248 | 0.92 | PARP1 (0.50) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL9052251 | 0.92 | PARP1 (0.50) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL30872577 | 0.91 | PARP1 (0.49) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL5081566 | 0.89 | PARP1 (0.52) | PARP1CA1CA2CA4CA9 | |
| SCHEMBL4312622 | 0.89 | PARP1 (0.52) | PARP1CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE | 2025-06-26 | — | — | US | disclosed |
| CN-119403551-A | Small molecule inhibitors of TEA domain family members | 斯克里普斯研究学院 | 2025-02-07 | — | — | CN | disclosed |
| EP-4496570-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | The Scripps Research Institute (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2024054512-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023183768-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-6313109-B2 | ANTIPROLIFERATIVE AGENTS; TREATING TUMORS, RESTENOSIS | SOCIETE DE CONSEILS DE RECHERCHES D'APPLICATIONS SCIENTIFIQUES, SAS (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-1094810-A1 | USE OF PRENYLTRANSFERASE INHIBITORS FOR PREPARING A MEDICINE FOR TREATING PATHOLOGIES RESULTING FROM HETEROTRIMERIC G PROTEIN MEMBRANE FIXATION | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-05-02 | — | — | EP | disclosed |
| US-20010000344-A1 | Prenyl transferase inhibitors | BIOMEASURE INCORPORATED | 2001-04-19 | — | — | US | disclosed |
| US-6180619-B1 | TREATING TUMORS OR RESTENOSIS | BIOMEASURE, INCORPORATED | 2001-01-30 | — | — | US | disclosed |
| WO-2000002558-A1 | USE OF PRENYLTRANSFERASE INHIBITORS FOR PREPARING A MEDICINE FOR TREATING PATHOLOGIES RESULTING FROM HETEROTRIMERIC G PROTEIN MEMBRANE FIXATION | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-01-20 | — | — | WO | disclosed |
| US-5929077-A | Thioproline-containing inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY | 1999-07-27 | — | — | US | disclosed |
| EP-0836383-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-22 | — | — | EP | disclosed |
| US-5736539-A | ANITCARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0703905-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1996-04-03 | — | — | EP | disclosed |
| WO-1995000497-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | YAP1, TEAD1, TEAD2 | PARP1 3884/4885CA1 4678/4885CA2 3241/4885 |
| US-20010000344-A1 | Prenyl transferase inhibitors | FNTA, FNTB, RCE1 | PARP1 2289/4885CA1 4614/4885CA2 4548/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PARP1 1128/4885CA1 3612/4885CA2 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.